Advertisement
U.S. markets close in 3 hours 53 minutes
  • S&P 500

    5,251.18
    +2.69 (+0.05%)
     
  • Dow 30

    39,778.28
    +18.20 (+0.05%)
     
  • Nasdaq

    16,382.08
    -17.44 (-0.11%)
     
  • Russell 2000

    2,134.29
    +19.94 (+0.94%)
     
  • Crude Oil

    82.67
    +1.32 (+1.62%)
     
  • Gold

    2,236.30
    +23.60 (+1.07%)
     
  • Silver

    24.92
    +0.16 (+0.66%)
     
  • EUR/USD

    1.0798
    -0.0032 (-0.29%)
     
  • 10-Yr Bond

    4.1830
    -0.0130 (-0.31%)
     
  • GBP/USD

    1.2629
    -0.0009 (-0.07%)
     
  • USD/JPY

    151.3560
    +0.1100 (+0.07%)
     
  • Bitcoin USD

    71,101.91
    +1,902.55 (+2.75%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,965.22
    +33.24 (+0.42%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Verrica (VRCA) in Focus: Stock Moves 8.9% Higher

Verrica Pharmaceuticals Inc. VRCA was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock, which remained volatile and traded within the range of $8.76-$15.12 in the past one-month time frame, witnessed a sharp increase on Friday.

The company has seen one positive estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Verrica. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Verrica currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.

Verrica Pharmaceuticals Inc. Price

Verrica Pharmaceuticals Inc. Price
Verrica Pharmaceuticals Inc. Price

Verrica Pharmaceuticals Inc. price | Verrica Pharmaceuticals Inc. Quote

Investors interested in the Medical – Drugs industry may consider Pacira BioSciences, Inc. PCRX, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Today's Best Stocks from Zacks 

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.

This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.

See their latest picks free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Pacira BioSciences, Inc. (PCRX) : Free Stock Analysis Report
 
Verrica Pharmaceuticals Inc. (VRCA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Advertisement